Dr. Patrick Forde, MD
Claim this profileJohns Hopkins University/Sidney Kimmel Cancer Center
Studies Lung Cancer
Studies Non-Small Cell Lung Cancer
10 reported clinical trials
19 drugs studied
Area of expertise
1Lung Cancer
Stage II
Stage I
Stage III
2Non-Small Cell Lung Cancer
Stage II
Stage I
Stage III
Affiliated Hospitals
Clinical Trials Patrick Forde, MD is currently running
Crizotinib
for Non-Small Cell Lung Cancer
This randomized phase III trial studies how well crizotinib works in treating patients with stage IB-IIIA non-small cell lung cancer that has been removed by surgery and has a mutation in a protein called anaplastic lymphoma kinase (ALK). Mutations, or changes, in ALK can make it very active and important for tumor cell growth and progression. Crizotinib may stop the growth of tumor cells by blocking the ALK protein from working. Crizotinib may be an effective treatment for patients with non-small cell lung cancer and an ALK fusion mutation.
Recruiting2 awards Phase 328 criteria
Immunotherapy + Chemotherapy
for Non-Small Cell Lung Cancer
This phase III ALCHEMIST trial tests the addition of pembrolizumab to usual chemotherapy for the treatment of stage IIA, IIB, IIIA or IIIB non-small cell lung cancer that has been removed by surgery. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Chemotherapy drugs, such as cisplatin, pemetrexed, carboplatin, gemcitabine hydrochloride, and paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving pembrolizumab with usual chemotherapy may help increase survival times in patients with stage IIA, IIB, IIIA or IIIB non-small cell lung cancer.
Recruiting2 awards Phase 327 criteria
More about Patrick Forde, MD
Clinical Trial Related10 years of experience running clinical trials · Led 10 trials as a Principal Investigator · 3 Active Clinical TrialsTreatments Patrick Forde, MD has experience with
- Durvalumab
- Carboplatin
- Nivolumab
- Paclitaxel
- Pembrolizumab
- Lobectomy
Breakdown of trials Patrick Forde, MD has run
Lung Cancer
Non-Small Cell Lung Cancer
Malignant Pleural Mesothelioma
Mesothelioma
Parotid Gland Cancer
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
What does Patrick Forde, MD specialize in?
Is Patrick Forde, MD currently recruiting for clinical trials?
Are there any treatments that Patrick Forde, MD has studied deeply?
What is the best way to schedule an appointment with Patrick Forde, MD?
What is the office address of Patrick Forde, MD?
Is there any support for travel costs?
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.